China Pharma Holdings, Inc

(NYSE MKT:CPHI)

Latest On China Pharma Holdings, Inc (CPHI):

Date/Time Type Description Signal Details
2023-02-25 05:15 ESTNewsChina Pharma launches 1-for-10 reverse stock splitN/A
2022-12-05 23:49 ESTNewsChina Pharma more than doubles on acquisition of dry eye disease therapeutic device projectN/A
2022-10-03 09:50 ESTNewsChina Pharma gets NYSE American listing deficiency noticeN/A
2022-07-19 01:41 ESTNewsChina Pharma files plan of compliance to NYSE AmericanN/A
2022-06-22 17:37 ESTNewsChina Pharma receives non-compliance letter from NYSE AmericanN/A
2022-04-01 04:34 ESTNewsChina Pharma GAAP EPS of -$0.07, revenue of $9.6MN/A
2021-03-30 04:05 ESTNewsDespite audit finding 'substantial doubt' about future, China Pharma shares soar 43% (updated)N/A
2021-03-27 19:30 ESTNewsAudit finds 'substantial doubt' about China Pharma's future; shares plummet 43%N/A
2020-12-13 03:40 ESTFinancialsCompany financials have been released.Neutral
2020-11-17 11:29 ESTFinancialsCompany financials have been released.Neutral
2020-11-14 00:04 ESTNewsChina Pharma reports Q3 resultsN/A
2020-11-07 15:29 ESTFinancialsCompany financials have been released.Neutral
2020-09-26 12:25 ESTFinancialsCompany financials have been released.Neutral
2020-09-17 04:33 ESTFinancialsCompany financials have been released.Neutral
2020-09-06 00:26 ESTFinancialsCompany financials have been released.Neutral
2020-08-16 08:26 ESTFinancialsCompany financials have been released.Neutral
2020-08-14 16:00 ESTNewsChina Pharma reports Q2 resultsN/A
2020-07-31 00:38 ESTFinancialsCompany financials have been released.Neutral
2020-07-23 16:41 ESTFinancialsCompany financials have been released.Neutral
2020-07-10 08:30 ESTFinancialsCompany financials have been released.Neutral
2020-07-01 08:27 ESTFinancialsCompany financials have been released.Neutral
2020-05-31 16:58 ESTFinancialsCompany financials have been released.Neutral
2020-05-20 12:34 ESTFinancialsCompany financials have been released.Neutral
2020-05-18 06:43 ESTNewsChina Pharma reports Q1 resultsN/A
2020-05-03 08:32 ESTFinancialsCompany financials have been released.Neutral
2020-04-23 20:15 ESTNewsCoronavirus plays - vaccines, drugs & infection control productsN/A
2020-04-23 20:12 ESTNewsFamiliar names gain as COVID-19 weighs on marketN/A
2020-04-23 20:10 ESTNewsCoronavirus plays on the move premarketN/A
2020-04-11 08:54 ESTNewsTiny firms riding coronavirus waveN/A
2020-04-11 08:17 ESTNewsChina Pharma reports FY resultsN/A
2020-04-07 12:28 ESTFinancialsCompany financials have been released.Neutral
2020-04-07 00:38 ESTFinancialsCompany financials have been released.Neutral
2020-04-01 16:21 ESTFinancialsCompany financials have been released.Neutral
2020-03-31 21:38 ESTNewsChina Pharma Holdings Inc. (CPHI) CEO Zhilin Li on Q4 2019 Results - Earnings Call TranscriptN/A
2020-02-28 23:29 ESTFinancialsCompany financials have been released.Neutral
2020-02-28 03:31 ESTFinancialsCompany financials have been released.Neutral
2020-02-21 23:24 ESTFinancialsCompany financials have been released.Neutral
2020-02-14 23:23 ESTFinancialsCompany financials have been released.Neutral
2020-02-06 23:26 ESTFinancialsCompany financials have been released.Neutral
2020-01-29 23:26 ESTFinancialsCompany financials have been released.Neutral
2020-01-28 03:31 ESTEarningsEarnings have been released on September 30, 2011, with $0.08 earnings per share.Sell
2020-01-28 03:31 ESTEarningsEarnings have been released on June 30, 2011, with $0.12 earnings per share.Buy
2020-01-28 03:31 ESTEarningsEarnings have been released on December 31, 2010, with $0.15 earnings per share.Sell
2020-01-27 23:24 ESTFinancialsCompany financials have been released.Neutral
2020-01-15 23:25 ESTFinancialsCompany financials have been released.Neutral
2019-12-21 23:16 ESTFinancialsCompany financials have been released.Neutral
2019-12-16 23:25 ESTFinancialsCompany financials have been released.Neutral
2019-11-27 23:24 ESTFinancialsCompany financials have been released.Neutral
2019-11-26 23:24 ESTFinancialsCompany financials have been released.Neutral
2019-11-22 23:22 ESTFinancialsCompany financials have been released.Neutral

About China Pharma Holdings, Inc (CPHI):

China Pharma Holdings, Inc. develops, manufactures, and markets generic and branded pharmaceutical, and biochemical products primarily to hospitals and private retailers in the People's Republic of China. The company offers products in the form of dry powder injectables, liquid injectables, tablets, capsules, and cephalosporin oral solutions. Its products include Cerebroprotein Hydroloysate injection to treat memory decline and attention deficit; Gastrodin injection for tiredness, loss of concentration, poor sleep, and traumatic syndromes of the brain; Propylgallate and Ozagrel Sodium to treat cerebral thrombosis, coronary heart disease, and after surgery complications; Alginic Sodium Diester injection for ischemic heart, cerebrovascular, and high lipoprotein blood diseases; Bumetanide to treat edema diseases; and Candesartan for hypertension. It also provides Roxithromycin dispersible tablets for pharyngitis and tonsillitis; Cefaclor dispersible tablets for tympanitis, lower respiratory tract infection, urinary tract infections, and skin/skin tissue infection; Cefalexin capsules for acute tonsillitis; Anhydroandrographolide for ischemic heart, cerebrovascular, and high lipoprotein blood diseases; Clarithromycin granules and capsules; and Naproxen Sodium and PseudophedrineHydrochlorida sustained release tablets. In addition, the company offers Hepatocyte growth-promoting factor, Tiopronin, Compound Ammonium Glycyrrhetate S, and Omeparzole for the treatment of digestive diseases. Further, it provides Vitamin B6 injection; and Granisetron Hydrochloride injection to treat nausea and vomiting caused by radiotherapy and chemotherapy during the treatment of malignant tumors. The company offers its products through distributors, as well as through its network of 16 sales offices and approximately 1,000 sales representatives. China Pharma Holdings, Inc. is headquartered in Haikou, the People's Republic of China.

CPHI Quotes by TradingView

See Advanced Chart

General

  • Name China Pharma Holdings, Inc
  • Symbol CPHI
  • Type Common Stock
  • Exchange NYSE MKT
  • Currency USD
  • Country USA
  • SectorHealthcare
  • IndustryDrug Manufacturers-Specialty & Generic
  • Full Time Employees 228
  • Last Split Factor1000:21804
  • Last Split Date2003-08-15
  • Fiscal Year EndDecember
  • IPO Date2002-04-17
  • Gic SectorHealth Care
  • Gic GroupPharmaceuticals, Biotechnology & Life Sciences
  • Gic IndustryPharmaceuticals
  • Gic SubIndustryPharmaceuticals
  • Web URLhttp://www.chinapharmaholdings.com
View More

Valuation

  • Price/Sales (Trailing 12 Mt.) 3.65
  • Price/Book (Most Recent Quarter) 5.34
  • Enterprise Value Revenue 4.25
View More

Financials

  • Most Recent Quarter 2020-09-30
  • Profit Margin -186%
  • Operating Margin -29%
  • Return on Assets -6%
  • Return on Equity -116%
  • Revenue 10.98 million
  • Earnings Per Share -$0.25
  • Revenue Per Share $0.25
  • Gross Profit 1.48 million
  • Quarterly Earnings Growth 1%
View More

Highlights

  • Market Capitalization 44.15 million
  • EBITDA 257212
  • Analyst Target Price $3
  • Book Value Per Share $0.18
View More

Share Statistics

  • Shares Outstanding 45.58 million
  • Shares Float 20.98 million
  • % Held by Insiders 4966%
  • % Held by Institutions 2.98%
  • Shares Short 200138
  • Shares Short Prior Month 116202
  • Short Ratio 0.08
  • Short % of Float 1%
View More

Technicals

  • Beta 0.25
  • 52 Week High $1.31
  • 52 Week Low $0.32
  • 50 Day Moving Average 0.94
  • 200 Day Moving Average 0.58
View More

Dividends

  • Dividend Date N/A
  • ExDividend Date N/A
  • Dividend Yield 0%
View More

China Pharma Holdings, Inc (CPHI) Dividend Calendar:

Ex-Dividend Date Payment Date Record Date Declared Date Amount

China Pharma Holdings, Inc (CPHI) Earnings History:

Companies typically report earnings on both a quarterly and annual basis. Earnings reported that deviate from analysts' expectations can have a large impact on a stock's price.


Quarter Date Report Date Actual Revenue Reported EPS EPS Estimate Deviation from Estimate
2020-09-302020-11-13$N/A-$0.02
2020-06-302020-09-30$N/A-$0.02
2020-03-312020-06-30$1.76 million$0.00
2019-12-312020-03-31$N/A-$0.02
2019-09-302019-12-31$2.38 million-$0.43
2019-06-302019-09-30$2.57 million-$0.02
2019-03-312019-06-30$2.93 million-$0.02
2018-12-312019-03-31$3.24 million-$0.01$0.00
2018-09-302018-12-31$2.3 million-$0.17
2018-06-302018-09-30$3.17 million-$0.04
2018-03-312018-06-30$3.62 million-$0.02
2017-12-312018-03-31$3.85 million-$0.01$0.00
2017-09-302017-12-31$3.16 million-$0.32
2017-06-302017-09-30$2.92 million-$0.05
2017-03-312017-06-30$3.29 million-$0.05
2016-12-312017-03-31$5.26 million-$0.02$0.00
2016-09-302016-12-31$3.13 million-$0.08
2016-06-302016-09-30$3.54 million-$0.04
2016-03-312016-06-30$3.64 million-$0.06
2015-12-312016-03-31$4.5 million-$0.04$0.00
2015-09-302015-12-31$4.48 million-$0.14
2015-06-302015-09-30$5.67 million$0.07
2015-03-312015-06-30$5.7 million-$0.09
2014-12-312015-03-31$3.33 million-$0.19$0.00
2014-09-302014-12-31$5.57 million-$0.51
2014-06-302014-09-30$6.13 million-$0.15
2014-03-312014-06-30$7.11 million-$0.20
2013-12-312014-03-31$8.42 million-$0.05
2013-09-302013-12-31$8.12 million-$0.24
2013-06-302013-09-30$8.03 million-$0.05
2013-03-312013-06-30$8.27 million-$0.10
2012-12-312013-03-31$11.65 million-$0.06
2012-09-302012-12-31$12.18 million-$0.03
2012-06-302012-09-30$14.6 million$0.03
2012-03-312012-06-30$16.09 million$0.04
2011-12-312012-03-31$22.46 million$0.06
2011-09-302011-12-31$20.99 million$0.09$0.12-25%
2011-06-302011-09-30$19.6 million$0.11$0.110%
2011-03-312011-06-30$18.12 million$0.12$0.12-2.75%
2010-12-312011-03-31$23.97 million$0.12$0.16-26.5%
2010-09-302010-12-31$18.68 million$0.15$0.1315.38%
2010-06-302010-08-10$16.63 million$0.12$0.119.09%
2010-03-312010-05-11$15.1 million$0.10$0.11-9.09%
2009-12-312010-03-05$19.58 million$0.12$0.14-14.29%
2009-09-302009-11-11$15.52 million$0.17$0.1241.67%
2009-06-302009-08-11$13.6 million$0.10$0.100%
2009-03-312009-05-15$12.99 million$0.09$0.13-30.77%
2008-12-312009-03-17$15.36 million$0.13$0.1118.18%
2008-09-302008-11-07$12.61 million$0.10$0.0911.11%
2008-06-302008-08-06$11.28 million$0.10$0.11-9.09%
2008-03-312008-05-02$11.72 million$0.11
2007-09-302007-11-15$8.29 million$0.08
2007-06-302007-08-14$8.57 million$0.09
2007-03-312007-05-15$7.23 million$0.07
2006-12-312006-12-31$0.10
2006-09-302006-11-14$0.05$0.050%
2006-06-302006-06-30$0.05
2006-03-312006-03-31$0.05
2005-06-302005-06-30-$2.09
2005-03-312005-03-31-$0.06
2004-12-312004-12-31-$0.03
2004-09-302004-09-30-$0.02
2004-06-302004-06-30-$0.16
2004-03-312004-03-31$0.01
2003-12-312003-12-31$-0.00
2003-09-302003-09-30-$0.89
2003-06-302003-06-30-$0.04
2003-03-312003-03-31-$0.25
2002-12-312002-12-31-$0.32
2002-09-302002-09-30$0.00
2002-06-302002-06-30-$1.68

China Pharma Holdings, Inc (CPHI) Company Financial Statements:

Financial statements are reports prepared by a company's management to present their financial performance and position at a point in time. A general-purpose set of financial statements usually includes a balance sheet, income statements, and statement of cash flows.

Income Statement:
Date
Research Development
Income Before Tax
Selling General Administrative
Gross Profit
Ebit
Operating Income
Income Tax Expense
Total Revenue
Cost of Revenue
Total Other Income Expense Net
Net Income From Continuing Operations
Net Income Applicable to Common Shares
Cash Flow:
Date
Investments
Change to Liabilities
Total Cash Flow from Investing Activities
Net Borrowings
Total Cash Flow from Financial Activities
Change to Operating Activities
Change in Cash
Total Cash from Operating Activities
Depreciation
Other Cash Flow from Investing Activities
Change to Inventory
Change to Account Receivables
Other Cash Flow from Financing Activities
Change to Net Income
Capital Expenditures
Balance Sheet:
Date
Total Liabailities
Total Stockholder Equity
Other Current Liabilities
Total Assets
Common Stock
Other Current Assets
Retained Earnings
Other Liabilities
Other Assets
Cash
Total Current Liabilities
Other Stockholder Equity
Property, Plant & Equipment
Total Current Assets
Long Term Investments
Net Tangible Assets
Short Term Investments
Long Term Debt
Inventory
Accounts Payable

China Pharma Holdings, Inc (CPHI) Chart:

China Pharma Holdings, Inc (CPHI) News:

Below you will find a list of latest news for China Pharma Holdings, Inc (CPHI) from major news sources. You can filter the results to only show news from a specific source.

No recent news available

China Pharma Holdings, Inc (CPHI) Options:

A stock option is a contract between two parties in which the stock option buyer (holder) purchases the right (but not the obligation) to buy/sell 100 shares of an underlying stock at a predetermined price from/to the option seller (writer) within a fixed period of time.

Expiration Date Strike Last Price Type Volume Open Interest Implied Volatility In The Money Change Change Percent

Latest CPHI Trades:

Date Shares Price
Jun 13, 2022 7:04 PM EST1000$0.245
Jun 13, 2022 7:04 PM EST400$0.245

China Pharma Holdings, Inc (CPHI) SEC Filings:

An SEC filing is a financial statement or other formal document submitted to the U.S. Securities and Exchange Commission (SEC). Public companies, certain insiders, and broker-dealers are required to make regular SEC filings.

Date Form Type Form Name Link
2020-05-1410-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1106644/000121390020012258/0001213900-20-012258-index.htm
2012-03-07UPLOADSEC-generated letterhttps://www.sec.gov/Archives/edgar/data/1106644/000000000012011860/0000000000-12-011860-index.htm
2012-02-14SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1106644/000091957412001550/0000919574-12-001550-index.htm
2013-02-12SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1106644/000091957413000765/0000919574-13-000765-index.htm
2012-02-10SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1106644/000093739412000076/0000937394-12-000076-index.htm
2012-02-13CORRESPCorrespondencehttps://www.sec.gov/Archives/edgar/data/1106644/000101054912000139/0001010549-12-000139-index.htm
2012-02-28CORRESPCorrespondencehttps://www.sec.gov/Archives/edgar/data/1106644/000101054912000205/0001010549-12-000205-index.htm
2012-03-028-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1106644/000101054912000215/0001010549-12-000215-index.htm
2012-03-06CORRESPCorrespondencehttps://www.sec.gov/Archives/edgar/data/1106644/000101054912000232/0001010549-12-000232-index.htm
2012-03-0610-Q/AQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1106644/000101054912000234/0001010549-12-000234-index.htm
2012-03-1410-KAnnual report [Section 13 and 15(d), not S-K Item 405]https://www.sec.gov/Archives/edgar/data/1106644/000101054912000255/0001010549-12-000255-index.htm
2012-04-308-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1106644/000101054912000438/0001010549-12-000438-index.htm
2012-05-014Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1106644/000101054912000445/0001010549-12-000445-index.htm
2012-05-1410-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1106644/000101054912000533/0001010549-12-000533-index.htm
2012-08-1410-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1106644/000101054912000896/0001010549-12-000896-index.htm
2012-11-09PRE 14AOther preliminary proxy statementshttps://www.sec.gov/Archives/edgar/data/1106644/000101054912001175/0001010549-12-001175-index.htm
2012-11-1410-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1106644/000101054912001213/0001010549-12-001213-index.htm
2012-11-19DEF 14AOther definitive proxy statementshttps://www.sec.gov/Archives/edgar/data/1106644/000101054912001246/0001010549-12-001246-index.htm
2012-12-268-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1106644/000101054912001324/0001010549-12-001324-index.htm
2013-01-048-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1106644/000101054913000005/0001010549-13-000005-index.htm
2013-03-1410-KAnnual report [Section 13 and 15(d), not S-K Item 405]https://www.sec.gov/Archives/edgar/data/1106644/000101054913000144/0001010549-13-000144-index.htm
2013-05-1410-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1106644/000101054913000329/0001010549-13-000329-index.htm
2013-08-1410-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1106644/000101054913000521/0001010549-13-000521-index.htm
2013-09-048-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1106644/000101054913000560/0001010549-13-000560-index.htm
2013-10-158-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1106644/000101054913000594/0001010549-13-000594-index.htm
2013-11-06DEF 14AOther definitive proxy statementshttps://www.sec.gov/Archives/edgar/data/1106644/000101054913000624/0001010549-13-000624-index.htm
2013-11-06DEFA14AAdditional definitive proxy soliciting materials and Rule 14(a)(12) materialhttps://www.sec.gov/Archives/edgar/data/1106644/000101054913000626/0001010549-13-000626-index.htm
2013-11-1410-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1106644/000101054913000676/0001010549-13-000676-index.htm
2013-12-178-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1106644/000101054913000745/0001010549-13-000745-index.htm
2014-03-2010-KAnnual report [Section 13 and 15(d), not S-K Item 405]https://www.sec.gov/Archives/edgar/data/1106644/000101054914000114/0001010549-14-000114-index.htm
2014-05-1510-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1106644/000101054914000242/0001010549-14-000242-index.htm
2014-08-1410-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1106644/000101054914000422/0001010549-14-000422-index.htm
2014-11-1410-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1106644/000101054914000619/0001010549-14-000619-index.htm
2014-11-20DEF 14AOther definitive proxy statementshttps://www.sec.gov/Archives/edgar/data/1106644/000101054914000633/0001010549-14-000633-index.htm
2014-11-21DEFA14CAdditional information statement materials, definitivehttps://www.sec.gov/Archives/edgar/data/1106644/000101054914000635/0001010549-14-000635-index.htm
2014-12-318-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1106644/000101054914000673/0001010549-14-000673-index.htm
2015-03-3010-KAnnual report [Section 13 and 15(d), not S-K Item 405]https://www.sec.gov/Archives/edgar/data/1106644/000101054915000090/0001010549-15-000090-index.htm
2015-05-1110-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1106644/000101054915000168/0001010549-15-000168-index.htm
2015-08-1410-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1106644/000101054915000256/0001010549-15-000256-index.htm
2015-10-29DEF 14AOther definitive proxy statementshttps://www.sec.gov/Archives/edgar/data/1106644/000101054915000313/0001010549-15-000313-index.htm
2015-10-29DEFA14AAdditional definitive proxy soliciting materials and Rule 14(a)(12) materialhttps://www.sec.gov/Archives/edgar/data/1106644/000101054915000314/0001010549-15-000314-index.htm
2015-11-1610-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1106644/000101054915000343/0001010549-15-000343-index.htm
2015-12-108-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1106644/000101054915000387/0001010549-15-000387-index.htm
2015-12-118-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1106644/000101054915000389/0001010549-15-000389-index.htm
2015-12-2810-K/AAnnual report [Section 13 and 15(d), not S-K Item 405]https://www.sec.gov/Archives/edgar/data/1106644/000101054915000416/0001010549-15-000416-index.htm
2015-12-2810-Q/AQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1106644/000101054915000418/0001010549-15-000418-index.htm
2015-12-2810-Q/AQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1106644/000101054915000420/0001010549-15-000420-index.htm
2015-12-2810-Q/AQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1106644/000101054915000422/0001010549-15-000422-index.htm
2016-03-3010-KAnnual report [Section 13 and 15(d), not S-K Item 405]https://www.sec.gov/Archives/edgar/data/1106644/000101054916000541/0001010549-16-000541-index.htm
2016-05-1610-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1106644/000101054916000606/0001010549-16-000606-index.htm
2016-08-1110-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1106644/000101054916000678/0001010549-16-000678-index.htm
2016-10-28DEF 14AOther definitive proxy statementshttps://www.sec.gov/Archives/edgar/data/1106644/000101054916000755/0001010549-16-000755-index.htm
2016-10-28DEFA14AAdditional definitive proxy soliciting materials and Rule 14(a)(12) materialhttps://www.sec.gov/Archives/edgar/data/1106644/000101054916000757/0001010549-16-000757-index.htm
2016-11-1410-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1106644/000101054916000787/0001010549-16-000787-index.htm
2016-12-028-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1106644/000101054916000834/0001010549-16-000834-index.htm
2016-12-138-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1106644/000101054916000864/0001010549-16-000864-index.htm
2016-12-288-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1106644/000101054916000877/0001010549-16-000877-index.htm
2017-03-3110-KAnnual report [Section 13 and 15(d), not S-K Item 405]https://www.sec.gov/Archives/edgar/data/1106644/000101054917000112/0001010549-17-000112-index.htm
2017-05-1110-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1106644/000101054917000167/0001010549-17-000167-index.htm
2012-02-15SC 13GStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1106644/000116613412000005/0001166134-12-000005-index.htm
2013-02-14SC 13GStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1106644/000116613413000006/0001166134-13-000006-index.htm
2017-03-318-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1106644/000121390017003047/0001213900-17-003047-index.htm
2017-08-1410-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1106644/000121390017008653/0001213900-17-008653-index.htm
2017-09-128-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1106644/000121390017009599/0001213900-17-009599-index.htm
2017-11-03DEF 14AOther definitive proxy statementshttps://www.sec.gov/Archives/edgar/data/1106644/000121390017011352/0001213900-17-011352-index.htm
2017-11-03DEFA14AAdditional definitive proxy soliciting materials and Rule 14(a)(12) materialhttps://www.sec.gov/Archives/edgar/data/1106644/000121390017011354/0001213900-17-011354-index.htm
2017-11-1410-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1106644/000121390017012067/0001213900-17-012067-index.htm
2017-12-188-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1106644/000121390017013370/0001213900-17-013370-index.htm
2018-03-128-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1106644/000121390018002824/0001213900-18-002824-index.htm
2018-04-0210-KAnnual report [Section 13 and 15(d), not S-K Item 405]https://www.sec.gov/Archives/edgar/data/1106644/000121390018003895/0001213900-18-003895-index.htm
2018-05-1410-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1106644/000121390018006100/0001213900-18-006100-index.htm
2018-08-1410-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1106644/000121390018010992/0001213900-18-010992-index.htm
2018-10-25DEF 14AOther definitive proxy statementshttps://www.sec.gov/Archives/edgar/data/1106644/000121390018014459/0001213900-18-014459-index.htm
2018-10-25DEFA14AAdditional definitive proxy soliciting materials and Rule 14(a)(12) materialhttps://www.sec.gov/Archives/edgar/data/1106644/000121390018014461/0001213900-18-014461-index.htm
2018-11-1410-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1106644/000121390018015783/0001213900-18-015783-index.htm
2018-12-068-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1106644/000121390018017006/0001213900-18-017006-index.htm
2019-03-2810-KAnnual report [Section 13 and 15(d), not S-K Item 405]https://www.sec.gov/Archives/edgar/data/1106644/000121390019005094/0001213900-19-005094-index.htm
2019-05-1410-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1106644/000121390019008566/0001213900-19-008566-index.htm
2019-08-1410-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1106644/000121390019015792/0001213900-19-015792-index.htm
2019-11-06DEF 14AOther definitive proxy statementshttps://www.sec.gov/Archives/edgar/data/1106644/000121390019022241/0001213900-19-022241-index.htm
2019-11-06DEFA14AAdditional definitive proxy soliciting materials and Rule 14(a)(12) materialhttps://www.sec.gov/Archives/edgar/data/1106644/000121390019022243/0001213900-19-022243-index.htm
2019-11-1410-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1106644/000121390019023467/0001213900-19-023467-index.htm
2019-12-238-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1106644/000121390019026825/0001213900-19-026825-index.htm
2020-03-3010-KAnnual report [Section 13 and 15(d), not S-K Item 405]https://www.sec.gov/Archives/edgar/data/1106644/000121390020008020/0001213900-20-008020-index.htm
2020-05-1410-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1106644/000121390020012258/0001213900-20-012258-index.htm
2020-08-1310-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1106644/000121390020021867/0001213900-20-021867-index.htm

China Pharma Holdings, Inc (CPHI) Insider Transactions:

Here you will find a list of insider trading activities (stock purchases, sales, and option exercises) reported by insiders of China Pharma Holdings, Inc (CPHI). Company insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise.
Insider Ownership: 4966%
Institutional Ownership: 298%

Transaction Date Insider Name Insider Title Type Shares Number Shares Price Total Transaction Shares Held After Transaction Link
2012-04-28FRANK WAUNGChief Financial OfficerBuy100,000.00138,415.00https://www.sec.gov/Archives/edgar/data/1106644/000101054912000445/0001010549-12-000445-index.htm